ClinicalTrials.gg
CompletedNCT01577459Updated Aug 21, 2018

A Phase 1 Crossover Study of Blood Pressure and Heart Rate Response

A Phase 1 interventional study of TR-701 FA with PSE and TR-701 FA Placebo with PSE in Healthy Subjects, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-21.

Sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a randomized, double-blinded, placebo-controlled, crossover study to evaluate the pressor effects of pseudoephedrine when administered with TR-701 FA in healthy adult volunteers.

Read the detailed description

Eligible subjects will be randomized to 1 of 2 possible treatment sequences (N=9 per sequence) on Study Day 1. Subjects will receive oral 200 mg TR 701 FA or Placebo for TR 701 FA once daily for 5 days during each treatment period, with a 2 day washout between periods (72 hours between doses). On Study Day 5 of each treatment period, subjects will also receive oral 60 mg PSE.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) is the lead sponsor of 19 studies on the registry; none are open to participants now.

First submitted before Trius Therapeutics LLC became part of Merck & Co., Inc.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects between 18 and 45 years of age, inclusive
  • Healthy males and females with no abnormalities identified by a detailed medical history
  • ≥ 19.0 kg/m2 and ≤ 31.0 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Systolic blood pressure > 130 mmHg or \< 90 mmHg measured after 10 minutes supine at the Screening Visit and Study Day 1
  • Diastolic blood pressure > 90 mmHg or \< 60 mmHg measured after 10 minutes supine at the Screening Visit and Study Day 1
  • Heart rate > 90 bpm or \< 50 bpm measured after 10 minutes supine at the Screening Visit and Study Day
  • Known allergy or to PSE
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    TR-701 FA with PSE

    TR-701 FA 200 mg oral with PSE

    Drug: TR-701 FA with PSE

  • Placebo comparator
    TR-701 FA Placebo with PSE

    TR-701 FA Placebo 200 mg oral with PSE

    Other: TR-701 FA Placebo with PSE

Interventions

  • DrugTR-701 FA with PSE

    Drug page: Tedizolid phosphate

    TR-701 FA Oral 200 mg oral with PSE

    Also known as: Tedizolid Phosphate

  • OtherTR-701 FA Placebo with PSE

    TR-701 FA Placebo Oral 200 mg with PSE

06

What researchers measure

Primary outcomes

  1. Systolic Blood Pressure

    To compare systolic blood pressure post administration of pseudoepherine concurrent with TR-701 FA and Placebo

    Time frame: 13 days

07

Study locations

1 site
  • Trius Investigator Site 001
    Overland Park, Kansas 66212, United States
08

References and documents

Publications

  • Flanagan S, Minassian SL, Prokocimer P. Pharmacokinetics of Tedizolid and Pseudoephedrine Administered Alone or in Combination in Healthy Volunteers. J Clin Med. 2018 Jun 14;7(6):150. doi: 10.3390/jcm7060150. PubMed 29899212 ↗
  • Flanagan S, Bartizal K, Minassian SL, Fang E, Prokocimer P. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrob Agents Chemother. 2013 Jul;57(7):3060-6. doi: 10.1128/AAC.00431-13. Epub 2013 Apr 22. PubMed 23612197 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2012 to primary completion in Jun 2012, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2012
First posted
Apr 13, 2012
StartActual
Apr 23, 2012
Primary completionActual
Jun 15, 2012
CompletionActual
Jun 15, 2012
Last update
Aug 21, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01577459
Responsible party
Sponsor
First posted
Apr 13, 2012
Start date
Apr 23, 2012
Primary completion
Jun 15, 2012
Completion
Jun 15, 2012
Last update
Aug 21, 2018

Study contacts

Philippe G Prokocimer, MD
study chair · Trius Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tedizolid phosphate

Start the discussion